E-viri
-
Huang, Wei-Chun; Hsieh, Song-Chou; Wu, Yen-Wen; Hsieh, Tsu-Yi; Wu, Yih-Jer; Li, Ko-Jen; Charng, Min-Ji; Chen, Wei-Sheng; Sung, Shih-Hsien; Tsao, Yen-Po; Ho, Wan-Jing; Lai, Chien-Chih; Cheng, Chin-Chang; Tsai, Hung-Cheng; Hsu, Chih-Hsin; Lu, Cheng-Hsun; Chiu, Yu-Wei; Shen, Chieh-Yu; Wu, Chun-Hsien; Liu, Feng-Cheng; Lin, Yen-Hung; Yeh, Fu-Chiang; Liu, Wei-Shin; Lee, Hui-Ting; Wu, Shu-Hao; Chang, Chi-Ching; Chu, Chun-Yuan; Hou, Charles Jia-Yin; Tsai, Chang-Youh
Acta Cardiologica Sinica, 03/2023, Letnik: 39, Številka: 2Journal Article
Background: Pulmonary arterial hypertension (PAH), defined as the presence of a mean pulmonary artery pressure >20 mmHg, pulmonary artery wedge pressure ≤ 15 mmHg, and pulmonary vascular resistance (PVR) > 2 Wood units based on expert consensus, is characterized by a progressive and sustained increase in PVR, which may lead to right heart failure and death. PAH is a well-known complication of connective tissue diseases (CTDs), such as systemic sclerosis, systemic lupus erythematosus, Sjogren's syndrome, and other autoimmune conditions. In the past few years, tremendous progress in the understanding of PAH pathogenesis has been made, with various novel diagnostic and screening methods for the early detection of PAH proposed worldwide. Objectives: This study aimed to obtain a comprehensive understanding and provide recommendations for the management of CTD-PAH in Taiwan, focusing on its clinical importance, prognosis, risk stratification, diagnostic and screening algorithm, and pharmacological treatment. Methods: The members of the Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) reviewed the related literature thoroughly and integrated clinical trial evidence and real-world clinical experience for the development of this consensus. Conclusions: Early detection by regularly screening at-risk patients with incorporations of relevant autoantibodies and biomarkers may lead to better outcomes of CTD-PAH. This consensus proposed specific screening flowcharts for different types of CTDs, the risk assessment tools applicable to the clinical scenario in Taiwan, and a recommendation of medications in the management of CTD-PAH.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.